Chest
Translating Basic Research Into Clinical PracticeCommon Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer
Section snippets
Genetics
Although the pathogenesis of IPF is not well understood there is a growing body of evidence that genetic variants may explain the risk of disease development and progression, as well as treatment response.10 Large genome wide-association studies have indicated that almost one-third of the risk of developing a fibrotic idiopathic interstitial pneumonia can be explained by genetic variants including MUC5B, telomerase, and surfactant-associated genes (Table 1).10 On the other hand, lung cancer
Conclusion
Current data support the idea that the coexistence of IPF and lung cancer cannot be coincidental. IPF and lung cancer may represent the complex result of immune privilege, that is, a metaplastic respiratory epithelium that evades immune surveillance due to interaction with a fibrotic stroma, which provides all necessary epigenetic signals that mediate neoplasia in genetically predisposed individuals. However, how diffuse interstitial lung abnormalities produce focal cancerous lesions is still
Acknowledgments
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: D. B. has received travel grants, consultancy fees, and money for patient enrollment/research completion and speaking activities from Hoffmann-La Roche and Boehringer Ingelheim. A. T. has received travel, honorary, and consultancy fees from Boehringer Ingelheim, Hoffmann-La Roche, Elpen, Chiesi, and AstraZeneca. V. T. has received travel fees from Boehringer Ingelheim and Hoffmann-La Roche. None declared (G.
References (68)
- et al.
Lung cancer in patients with idiopathic pulmonary fibrosis
Pulm Pharmacol Ther
(2017) - et al.
A clinicopathological study of surgically resected lung cancer in patients with usual interstitial pneumonia
Respir Med
(2017) - et al.
The impact of lung cancer on survival of idiopathic pulmonary fibrosis
Chest
(2015) - et al.
Patients with IPF and lung cancer: diagnosis and management
Lancet Respir Med
(2018) - et al.
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
Lancet Respir Med
(2019) - et al.
Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer
Am J Hum Genet
(2009) - et al.
Clinicopathological, immunohistochemical, and genetic features of primary lung adenocarcinoma occurring in the setting of usual interstitial pneumonia pattern
J Thorac Oncol
(2016) - et al.
An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study
Lancet Respir Med
(2017) - et al.
High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer
Eur J Cancer
(2013) - et al.
Aberrant Wnt/β-catenin pathway activation in idiopathic pulmonary fibrosis
Am J Pathol
(2003)
A shared pattern of β-catenin activation in bronchopulmonary dysplasia and idiopathic pulmonary fibrosis
Am J Pathol
PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition
Lab Invest
A phosphoinositide 3-kinase-γ inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats
Biochem Biophys Res Commun
Complexity in the tumour microenvironment: cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types
Semin Cancer Biol
TGFβ pathway inhibition in the treatment of non-small cell lung cancer
Pharmacol Ther
Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study
EBioMedicine
Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis
Clin Lung Cancer
Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone
Respir Investig
Effect of perioperative pirfenidone treatment in lung cancer patients with idiopathic pulmonary fibrosis
Ann Thorac Surg
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
Am J Respir Crit Care Med
Idiopathic pulmonary fibrosis
Nat Rev Dis Primers
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Eur Respir J
Cumulative incidence of and predictive factors for lung cancer in IPF
Respirology
Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment
Front Med (Lausanne)
The genetic basis of idiopathic pulmonary fibrosis
Eur Respir J
Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer
Hum Mol Genet
Telomerase mutations in families with idiopathic pulmonary fibrosis
N Engl J Med
Telomere length, COPD and emphysema as risk factors for lung cancer
Eur Respir J
Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer
Oncol Rep
How strong is the association between IPF and lung cancer? An answer from airway’s DNA
Med Oncol
Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
MYCL1, FHIT, SPARC, p16INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis
J Cell Mol Med
Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses
Respir Res
Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis
J Pathol
Cited by (0)
Drs Tzouvelekis and Gomatou contributed equally to this manuscript.